相关实验视频

Updated: Jul 15, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

解读leucodelphinidin作为一个双抗氧化剂和抗糖尿病候选人的新维度:DFT,对接和动态评估

Sheeba Veronica Jesu Ignasious¹, Sadasivam Kandasamy¹

¹Department of Physics, Bannari Amman Institute of Technology, Sathyamangalam, Tamil Nadu, India.

Biophysical chemistry

|March 13, 2026

概括

柳科德尔菲尼丁 (LDN) 是一种强大的抗氧化剂和抗糖尿病类黄. 计算研究揭示了其激素清除机制以及调节氧化应激和对代谢障碍的葡萄糖调节的潜力.

科学领域:

生物化学生物化学
计算化学计算化学
药理学药理学是指药理学的学科.

背景情况:

柳科德尔菲尼丁 (LDN) 具有潜在的抗氧化和抗糖尿病特性.
了解它的机制对于治疗开发至关重要.

研究的目的:

通过计算来评估LDN的激素清理机制.
研究LDN与参与葡萄糖调节的关键酶的相互作用.
探索LDN对代谢障碍的潜在治疗应用.

主要方法:

密度功能理论 (DFT) 用于根基清理途径 (HAT,SET-PT,SPLET).
对各种热力学和电子参数 (BDE,ETE,PA,EA,PDE,IP) 的分析.
分子对接和动力学 (MD) 模拟与人类葡萄糖酶和胰腺α-氨酶.

主要成果:

DFT分析阐明了LDN的多路径基因清除机制.
欧洲议会议员和FMO的分析确定了易受激进攻击的富含电子的区域.
分子对接和MD模拟表明LDN与目标酶的相互作用,表明葡萄糖调节潜力.

结论:

通过多个途径,LDN拥有显著的激进清理能力.
计算发现突出了LDN在减轻氧化应激和调节葡萄糖代谢方面的双重作用.
LDN成为氧化应激相关代谢障碍的有前途的治疗.

关键词:

在 DFT 方面,它是最重要的.治疗糖尿病治疗糖尿病停靠对接停靠对接动力学动力学动力学莱科德尔菲尼迪尼是什么意思?氧化应激是一种氧化应激.药理动力学药理动力学

更多相关视频

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...